For example, RHAMM silencing blocked the self-renewing capability of glioblastoma stem cells, and loss of RHAMM in malignant peripheral nerve sheath tumors or multiple myeloma enhances the sensitivity of tumor cells to AURKA inhibitors. Here, HMMR is linked to malignant peripheral nerve sheath tumor.